Frontiers in Bioscience-Landmark (Aug 2024)

IFITM10 Enhance Tumor Angiogenesis and Promotes Cancer Progression through STAT3 Activation

  • Youjian Li,
  • Mengjie Wang,
  • Xun Li,
  • Jiehong Jia,
  • Fei Pan,
  • Wen Li,
  • Zhongzhu Chen,
  • Dianyong Tang,
  • Kepeng Ou

DOI
https://doi.org/10.31083/j.fbl2908283
Journal volume & issue
Vol. 29, no. 8
p. 283

Abstract

Read online

Background: Humankind have been struggling with colorectal cancer (CRC) for long period with its rapid progression and invasive metastasis. By hyperactivating IL-6/STAT3 signaling, CRC facilitates the capacity of angiogenesis to plunder massive nutrients and develops gradually under harsh condition. Methods: The Cancer Genome Atlas database was analyzed for acquiring interferon-γ inducible protein 10 (IFITM10) expression levels and their correlation with clinical outcomes. The cell angiogenic ability were assessed by Cell Counting Kit-8 (CCK-8) and tube formation assay. Immunofluorescence, Western blot, and enzyme-linked immunosorbent assay (ELISA) assay were using to assess potential mechanism. Results: In our study, we find that IFITM10 is upregulated in CRC and is positively related with tumor angiogenesis. We also find that IFITM inhibition decreased STAT3 phosphorylation level and IFITM10-mediated angiogenesis depends on STAT3 activation. Furthermore, our data suggests that IFITM10 may be a key prognostic biomarker in colorectal cancer. Conclusion: Together, our study suggests that IFITM10 enhance angiogenesis through STAT3 activation during CRC progression, which highlighting its potency as a therapeutic target for colorectal cancer.

Keywords